Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® or Placebo.
Launched by HRA PHARMA · Mar 30, 2012
Trial Information
Current as of June 19, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Healthy women aged 18-35 years old
- • BMI \< 30 Kg/m2
- • Not at risk of pregnancy
- • No use of progesterone-only-pill for 3 months before start of treatment cycle
- • No use of implant hormonal contraception for 3 months before start of treatment cycle
- • No use of levonorgestrel intrauterine system for 3 months before start of treatment cycle
- • No use of depo provera for 12 months before start of treatment cycle
- • Able to give informed consent.
About Hra Pharma
HRA Pharma is a leading global pharmaceutical company focused on developing innovative healthcare solutions that address unmet medical needs. With a commitment to advancing patient care, HRA Pharma specializes in the research and development of products in areas such as women's health, endocrinology, and rare diseases. The company leverages a strong pipeline of clinical trials to deliver safe and effective therapies, while prioritizing ethical standards and regulatory compliance in all its operations. HRA Pharma's dedication to scientific excellence and patient-centric approaches positions it as a key player in the pharmaceutical industry, driving progress in healthcare for diverse populations worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stockholm, , Sweden
Groningen, , Netherlands
Edinburgh, Scotland, United Kingdom
Patients applied
Trial Officials
Sharon Cameron, MD
Principal Investigator
Chalmers Sexual Health Clinic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials